- Do you own shares of NuPathe Inc. (NASDAQ GM: PATH )?
- Did you purchase any of your shares prior to December 16, 2013?
- Do you think the proposed buyout price is too low?
- Do you want to discuss your rights?
Teva (TEVA) will pay $3.65 in cash per share of NuPathe (PATH).
Endo Pharma is buying Nupathe and its migraine armband for a 24% premium.